Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aurinia/3SBio Drug Effective against Lupus Nephritis

publication date: Feb 24, 2016
Canada's Aurinia Pharma reported Luveniq (voclosporin), a potential treatment for lupus nephritis, produced positive data in early results from a Phase IIb trial, currently underway in Malaysia. 3SBio licensed China rights to the drug in 2010. Out of 7 patients with the disease, there were four with complete remission at week eight and a mean reduction in proteinuria (abnormal quantities of protein in urine) of 72%, also at week eight. Complete results of the trial are expected in Q3 of 2016. More details....

Stock Symbols: (TSX: AUP; NSDQ: AUPH) (HK: 1530)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here